Top US Drugmakers Exploit US Patent System To Keep Generic Competition At Bay: Report
Citing the Initiative for Medicines, Access & Knowledge’s (I-MAK) report, Reuters said that several makers of top-selling drugs…
Looking At Bristol-Myers Squibb’s Recent Whale Trades
A whale with a lot of money to spend has taken a noticeably bearish stance on Bristol-Myers Squibb.
Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 10 strange trades.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
These 5 Experts See A Market Crash Ahead: What Do BZ Readers Think?
A majority of Benzinga readers, 63.5%, expect the S&P 500 to hit a new low in September, according to a recent survey. More than 36% say it won't.
US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing
As part of President Joe Biden’s executive order to beef up U.S. biomanufacturing, the U.S. Department of Health and Human…
How Is The Market Feeling About Bristol-Myers Squibb?
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 5.36% since its last report. The company recently reported that it has 22.71 million shares sold short, which is 1.06% of all regular shares that are available for trading.
Benzinga’s Top Ratings Upgrades, Downgrades For September 14, 2022
Upgrades
For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low of $2.89. Moreover, at the end of the last trading period, the closing price was at $4.26.
US Stock Futures Rise After Recording Worst Sell-Off Since June 2020; PPI Data In Focus
Pre-open movers
U.S. stock futures traded higher in early pre-market trade on Wednesday after recording sharp losses on Tuesday following the release of inflation data for August. All the three major indices settled sharply lower, notching their biggest single-session percentage declines since June 2020.
Berenberg Downgrades Bristol-Myers Squibb to Hold, Lowers Price Target to $76
Berenberg analyst Luisa Hector downgrades Bristol-Myers Squibb (NYSE:BMY) from Buy to Hold and lowers the price target from $82 to $76.
Biden Administration Pushes ‘Cancer Moonshot’ Initiative: Report
President Joe Biden channeled John F. Kennedy on the 60th anniversary of the former President's moonshot speech, highlighting the Biden administration's efforts to "end cancer as we know it."
The President underscored his goal to cut the cancer death rate in the U.S. by at least 50% over the next 25 years.